Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV004520952 | SCV005036733 | uncertain significance | Cardiovascular phenotype | 2024-02-22 | criteria provided, single submitter | clinical testing | The p.A1022E variant (also known as c.3065C>A), located in coding exon 37 of the CACNA2D1 gene, results from a C to A substitution at nucleotide position 3065. The alanine at codon 1022 is replaced by glutamic acid, an amino acid with dissimilar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV005100756 | SCV005771905 | uncertain significance | Brugada syndrome | 2024-04-24 | criteria provided, single submitter | clinical testing | This sequence change replaces alanine, which is neutral and non-polar, with glutamic acid, which is acidic and polar, at codon 1022 of the CACNA2D1 protein (p.Ala1022Glu). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This variant has not been reported in the literature in individuals affected with CACNA2D1-related conditions. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |